FoundationOne Liquid
FoundationOne®CDx Technical Information Foundation Medicine, Inc. 150 Second Street, Cambridge, MA 02141 Phone: 617.418.2200 I
Comprehensive genomic profiling in oncology – from vision to reality | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
FDA approves Foundation Medicine pan-tumor liquid biopsy test
FoundationOne Liquid CDx
With its liquid biopsy approval, Foundation Medicine takes on Guardant | Evaluate
Foundation Medicine on LinkedIn: Join Foundation Medicine's Lucas Dennis, VP of Franchise Development, for…
Foundation Medicine receives FDA approval for pan-tumour biopsy test
Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne®Liquid in the Third Stage of SCRUM-Japan | Business Wire
Roche France, Foundation Medicine and the Institute Gustave Roussy announce unique partnership to provide in-house liquid biopsy genomic testing to cancer patients in France | Gustave Roussy
Foundation Medicine wins FDA OK for pan-cancer liquid biopsy test
First Comprehensive Next-gen Sequencing based Pan-Tumor Liquid Biopsy Test Approved - Onco'Zine
Multi-gene Testing (NGS) for PIK3CA Mutations
Foundation Medicine Acquires Lexent Bio, Inc., to Accelerate Liquid Biopsy Research and Development, and Advance Cancer Care
Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test - MedCity News
fmi-10k_20171231.htm
Foundation Medicine launches liquid biopsy test - MedCity News
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company's Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer | Technology Networks
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer | Nature Communications
Foundation Medicine acquires liquid biopsy developer Lexent Bio | Fierce Biotech
Latest Medical News
Compare Our Tests | Foundation Medicine
AACR 2019 – Foundation Medicine sets the scene for liquid biopsy approval | Evaluate
Foundation Medicine to launch liquid biopsy companion diagnostic following FDA approval - MedCity News
Multi-gene Testing (NGS) for PIK3CA Mutations
